CN114832099A - 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 - Google Patents
一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 Download PDFInfo
- Publication number
- CN114832099A CN114832099A CN202210368066.0A CN202210368066A CN114832099A CN 114832099 A CN114832099 A CN 114832099A CN 202210368066 A CN202210368066 A CN 202210368066A CN 114832099 A CN114832099 A CN 114832099A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cov
- sars
- variant strain
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 57
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 56
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 20
- 150000002148 esters Chemical class 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 abstract description 22
- 241000831652 Salinivibrio sharmensis Species 0.000 abstract description 20
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 abstract description 6
- 230000007969 cellular immunity Effects 0.000 abstract description 6
- 239000000427 antigen Substances 0.000 abstract description 5
- 102000036639 antigens Human genes 0.000 abstract description 5
- 238000013473 artificial intelligence Methods 0.000 abstract description 5
- 241000711573 Coronaviridae Species 0.000 abstract description 4
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 2
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 229940126582 mRNA vaccine Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940126583 recombinant protein vaccine Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 1
- FODVBOKTYKYRFJ-CIUDSAMLSA-N Asn-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N FODVBOKTYKYRFJ-CIUDSAMLSA-N 0.000 description 1
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 1
- OOXUBGLNDRGOKT-FXQIFTODSA-N Asn-Ser-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OOXUBGLNDRGOKT-FXQIFTODSA-N 0.000 description 1
- QIRJQYQOIKBPBZ-IHRRRGAJSA-N Asn-Tyr-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QIRJQYQOIKBPBZ-IHRRRGAJSA-N 0.000 description 1
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- XUVTWGPERWIERB-IHRRRGAJSA-N Asp-Pro-Phe Chemical compound N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O XUVTWGPERWIERB-IHRRRGAJSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- QQOWCDCBFFBRQH-IXOXFDKPSA-N Cys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N)O QQOWCDCBFFBRQH-IXOXFDKPSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- LMPBBFWHCRURJD-LAEOZQHASA-N Gln-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N LMPBBFWHCRURJD-LAEOZQHASA-N 0.000 description 1
- ZDJZEGYVKANKED-NRPADANISA-N Gln-Cys-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O ZDJZEGYVKANKED-NRPADANISA-N 0.000 description 1
- VGTDBGYFVWOQTI-RYUDHWBXSA-N Gln-Gly-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VGTDBGYFVWOQTI-RYUDHWBXSA-N 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 1
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 1
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- YYXJFBMCOUSYSF-RYUDHWBXSA-N Gly-Phe-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYXJFBMCOUSYSF-RYUDHWBXSA-N 0.000 description 1
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 1
- GBMSSORHVHAYLU-QTKMDUPCSA-N His-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N)O GBMSSORHVHAYLU-QTKMDUPCSA-N 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 1
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- YVSHZSUKQHNDHD-KKUMJFAQSA-N Lys-Asn-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N YVSHZSUKQHNDHD-KKUMJFAQSA-N 0.000 description 1
- DZQYZKPINJLLEN-KKUMJFAQSA-N Lys-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O DZQYZKPINJLLEN-KKUMJFAQSA-N 0.000 description 1
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- UIJVKVHLCQSPOJ-XIRDDKMYSA-N Lys-Ser-Trp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O UIJVKVHLCQSPOJ-XIRDDKMYSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- CGUYGMFQZCYJSG-DCAQKATOSA-N Met-Lys-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CGUYGMFQZCYJSG-DCAQKATOSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 1
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 1
- OMHMIXFFRPMYHB-SRVKXCTJSA-N Phe-Cys-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OMHMIXFFRPMYHB-SRVKXCTJSA-N 0.000 description 1
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 1
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 1
- RVEVENLSADZUMS-IHRRRGAJSA-N Phe-Pro-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RVEVENLSADZUMS-IHRRRGAJSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 description 1
- KAAPNMOKUUPKOE-SRVKXCTJSA-N Ser-Asn-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KAAPNMOKUUPKOE-SRVKXCTJSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- VEVYMLNYMULSMS-AVGNSLFASA-N Ser-Tyr-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEVYMLNYMULSMS-AVGNSLFASA-N 0.000 description 1
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 1
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- IBBBOLAPFHRDHW-BPUTZDHNSA-N Trp-Asn-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N IBBBOLAPFHRDHW-BPUTZDHNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 1
- RYSNTWVRSLCAJZ-RYUDHWBXSA-N Tyr-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RYSNTWVRSLCAJZ-RYUDHWBXSA-N 0.000 description 1
- MPKPIWFFDWVJGC-IRIUXVKKSA-N Tyr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O MPKPIWFFDWVJGC-IRIUXVKKSA-N 0.000 description 1
- TYFLVOUZHQUBGM-IHRRRGAJSA-N Tyr-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TYFLVOUZHQUBGM-IHRRRGAJSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- OBKOPLHSRDATFO-XHSDSOJGSA-N Tyr-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OBKOPLHSRDATFO-XHSDSOJGSA-N 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- DCOOGDCRFXXQNW-ZKWXMUAHSA-N Val-Asn-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N DCOOGDCRFXXQNW-ZKWXMUAHSA-N 0.000 description 1
- GXAZTLJYINLMJL-LAEOZQHASA-N Val-Asn-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GXAZTLJYINLMJL-LAEOZQHASA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 1
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 1
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 1
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种用于治疗SARS‑CoV‑2变异毒株感染的多肽制剂,一种用于治疗SARS‑CoV‑2变异毒株感染的多肽制剂,所述的多肽制剂包含如SEQ ID NO.1‑SEQ ID NO.20所示的多肽。本发明的优点为:该多肽是基于人工智能算法预测SARS‑CoV‑2变异毒株B.1.617.2的特异性抗原肽,经过化学合成生成的多肽刺激免疫细胞,个体体内存在的SARS‑CoV‑2变异毒株B.1.617.2特异性T细胞会产生应答,分泌细胞因子发挥细胞免疫作用。本发明提出的多肽对Delta型新型冠状病毒能引起细胞免疫反应,适用目前临床SARS‑CoV‑2印度变异毒株B.1.617.2感染的治疗。
Description
技术领域
本发明涉及免疫学和生物医药领域,具体地说是一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂。
背景技术
多肽疫苗是按照病原体抗原基因中已知或预测的某段抗原表位的氨基酸序列,通过化学合成技术制备的肽段混合物。多肽疫苗具有抗病毒、抗肿瘤、抗细菌、抗寄生虫感染功能。由于多肽疫苗价廉、安全、特异性强、容易保存和应用的优点,越来越受到重视。
目前全球研发的SARS-CoV-2疫苗主要包括减毒活疫苗、灭活疫苗、病毒载体疫苗、重组蛋白疫苗、多肽疫苗、DNA疫苗、mRNA疫苗等,上述疫苗均可激活体液免疫产生中和性抗体,但是减毒活疫苗、灭活疫苗、病毒载体疫苗、重组蛋白疫苗、DNA疫苗、mRNA疫苗均无法清除已被病毒感染的细胞。而多肽疫苗可特异性激活T细胞免疫,清除已被病毒感染的细胞,另外,多肽疫苗还具有可快速合成,开发与制备周期较短,可预防、可治疗等优点,因此,本发明提出了一种用于治疗SARS-CoV-2变异毒株B.1.617.2感染的多肽制剂。
发明内容
本发明之目的是弥补上述之不足,向社会公开安全性好、合成方便的一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂。
本发明的技术方案是这样实现的:
一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂,所述的多肽制剂包含如SEQID NO.1-SEQ ID NO.20所示的多肽。
一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂的应用,应用在药学上可接受的盐或酯或前药,所述的盐或酯或前药包含如SEQ ID NO.1-SEQ ID NO.20所示的多肽。
本发明多肽制剂的开发主要包括以下几个步骤:
步骤一、利用人工智能算法预测并筛选对T细胞高亲和力的抗原肽段:
使用SARS-CoV-2变异毒株B.1.617.2的S、E、N、M蛋白序列与I类HLA进行亲和力预测,基于肽段与HLA亲和力、肽段的水溶性、免疫原性等指标筛选与HLA结合IC50低于500nM、水溶性强、免疫原性强的9氨基酸(9-mer)肽段,并在肽段两端延长5个氨基酸得到19氨基酸(19-mer)肽段。
步骤二、利用化学合成法合成多肽:
利用化学合成法合成预测的20条SARS-CoV-2变异毒株B.1.617.2特异性多肽。
步骤三、收集Delta型新冠病毒感染康复者的全血,分离PBMC(peripheral bloodmononuclear cells):
在某医院收集SARS-CoV-2变异毒株B.1.617.2感染康复患者的临床信息与全血样本,全血取于绿色抗凝管中,每个个体收集全血16ml,并于6小时内分离PBMC用于实验或-80℃冻存。
步骤四、体外免疫系统激活实验验证HLA分型对应的多肽激活T细胞免疫的有效性:
PBMC细胞与合成的肽段疫苗共培养,采用酶联免疫斑点(Enzyme-linkedimmunospot,ELISpot)方法检测激活的T细胞IFN-γ分泌水平,在体外实验验证多肽的有效性。
本发明与现有技术相比的优点是:
本发明提出一种用于治疗SARS-CoV-2印度变异毒株B.1.617.2感染的多肽。该多肽是基于人工智能算法预测SARS-CoV-2变异毒株B.1.617.2的特异性抗原肽,经过化学合成生成的多肽刺激免疫细胞,个体体内存在的SARS-CoV-2变异毒株B.1.617.2特异性T细胞会产生应答,分泌细胞因子发挥细胞免疫作用。本发明提出的多肽对Delta型新型冠状病毒能引起细胞免疫反应,适用目前临床SARS-CoV-2印度变异毒株B.1.617.2感染的治疗。
附图说明
图1是本发明多肽制剂实验结果图;
图2是本发明多肽制剂实验结果统计图。
具体实施方式
下面结合附图进一步详细描述本发明:
一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂,所述的多肽制剂包含如SEQID NO.1-SEQ ID NO.20所示的多肽。
一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂的应用,应用在药学上可接受的盐或酯或前药,所述的盐或酯或前药包含如SEQ ID NO.1-SEQ ID NO.20所示的多肽。
本发明提出一种用于治疗SARS-CoV-2印度变异毒株B.1.617.2感染的多肽。该多肽是基于人工智能算法预测SARS-CoV-2变异毒株B.1.617.2的特异性抗原肽,经过化学合成生成的多肽刺激免疫细胞,个体体内存在的SARS-CoV-2特异性T细胞会产生应答,分泌细胞因子发挥细胞免疫作用。本发明提出的多肽对Delta型新型冠状病毒能引起细胞免疫反应,适用目前临床SARS-CoV-2印度变异毒株B.1.617.2感染的治疗。下面通过实验证明本发明多肽制剂在治疗SARS-CoV-2变异毒株B.1.617.2感染上的有效性。
如图1所示,本发明多肽制剂的开发过程以下几个步骤:
步骤一、预测多肽:
通过人工智能算法构建模型,输入SARS-CoV-2变异毒株B.1.617.2的S、E、N、M和ORFs蛋白序列和HLA序列信息可以获取与该HLA分型的高亲和力多肽序列。根据肽段与HLA亲和力、肽段的水溶性、免疫原性等指标筛选与HLA结合IC50低于500nM、水溶性强、免疫原性强的肽段。预测得到20条免疫肽段。
20条免疫肽段如下:
步骤二、合成多肽:
利用化学合成法合成预测的SARS-CoV-2变异毒株B.1.617.2特异性多肽,每种肽段纯度>95%,共合成5mg肽段。取1mg溶于100μl无菌水中,制成母液,接着取一部分母液使用无菌水进行稀释,配制成工作液为200μg/ml。
步骤三、收集新冠病毒感染康复者的全血,分离PBMC(peripheral bloodmononuclear cells):
在某医院收集SARS-CoV-2变异毒株B.1.617.2感染康复患者血液于绿色抗凝管中,每个个体收集血液16ml,并于6小时内分离PBMC用于实验或-80°冻存。首先将血液转移到干净的50ml离心管中,2000rpm,20℃离心10分钟;收集上层血清,-80℃冻存;向SepMateTM-50管底部加入Ficoll-Paque Premium 1.077溶液,再向沉淀物中加入等体积的PBS,稀释血样并轻轻混合保持试管垂直,将稀释后的样品沿管壁加入SepMateTM-50管中,1200xg离心15min;然后将上层溶液离心并转移到一个新的50ml无菌离心管中,用PBS清洗沉淀物,共清洗2次;使用红细胞裂解液裂解细胞3分钟;最后用细胞冻存液悬浮细胞,被储存在液氮中,以便将来用于检测或直接用培养基悬浮用于检测。
步骤四、体外免疫系统激活实验验证HLA分型对应的多肽激活T细胞免疫的有效性:
a)细胞复苏并计数:从液氮中取出冻存PBMC细胞,于37℃水浴快速解冻。完全解冻后,台盼蓝染色计数活细胞数量。
b)细胞培养:按每孔5*10^6个细胞铺于24孔板。加入IL-2(工作浓度20U/ml)、IL-7(工作浓度20ng/ml)、合成的所有肽段(工作浓度2μg/ml),于37℃(含5%CO2)细胞培养箱培养10天。培养期间每三天半换液。
c)收细胞:培养10天后收取细胞。将细胞转移到离心管中,使用1*PBS清洗细胞3次,以去除培养液中的IFN-γ。使用1640培养液(含10%FBS)重悬细胞,并计数。
d)准备ELISpot板:配置35%乙醇,每孔加入35%乙醇孵育1min。无菌H2O洗涤5遍。每孔加100μl包被抗体(工作浓度15μg/ml),4-8℃过夜孵育。
e)孵育细胞:用无菌1*PBS洗板5次。每孔加1640培养液(含10%FBS),置于室温孵育至少30min。弃上清,加入细胞悬浮液,每孔细胞数2×10^4-2.5×10^5。
f)加入刺激物共培养:不含诱导物-H2O(阴性对照组):加入无菌H2O 2μl;PHA刺激(阳性对照组):每孔加入10μl PHA(工作浓度2.5ug/ml);肽段刺激(实验组):每孔加入20条肽段混合肽池1μl(工作浓度2μg/ml)。把板置于37℃培养箱(5%CO2),培养12-48小时。
g)显色:吸走细胞,用无菌1*PBS洗板5次。每孔加100ul检测抗体(工作浓度1μg/ml),室温孵育2h。用无菌1*PBS洗板5次。每孔加100ul Streptavidin-HRP,室温孵育1h。用无菌1*PBS洗板5次。每孔加入显色剂,室温避光孵育5-10min。
h)终止:加入无菌H2O终止。吸走上清,无菌H2O清洗3遍,晾干板,解剖镜下检测并统计斑点数。
i)结果分析:本实验收集4名SARS-CoV-2变异毒株B.1.617.2感染康复者的外周血分离PBMC,利用预测的多肽池进行体外刺激实验。结果发现4名康复者的PBMC经过肽池刺激后均可产生强烈的T细胞反应,并具有统计学意义(如图1和图2所示,图1中Pos.con.为阳性对照结果;Pep.pool为20条肽段共刺激结果;Neg.con.为阴性对照结果;2位Delta型康复者编号为D01、D02)。该肽池可显著引起患者体内的SARS-CoV-2变异毒株B.1.617.2特异性T细胞反应,可用于SARS-CoV-2变异毒株B.1.617.2感染的治疗。
本发明的最佳实施例已被阐明,由本领域普通技术人员做出的各种变化或改型都不会脱离本发明的范围。
序列表
<110> 国科宁波生命与健康产业研究院
<120> 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 17
<212> PRT
<213> Homo sapiens
<400> 1
Val Ser Ser Gln Cys Val Asn Leu Arg Thr Arg Thr Gln Leu Pro Pro
1 5 10 15
Ala
<210> 2
<211> 16
<212> PRT
<213> Homo sapiens
<400> 2
Phe Cys Asn Asp Pro Phe Leu Asp Val Tyr Tyr His Lys Asn Asn Lys
1 5 10 15
<210> 3
<211> 15
<212> PRT
<213> Homo sapiens
<400> 3
Lys Asn Asn Lys Ser Trp Met Lys Ser Gly Val Tyr Ser Ser Ala
1 5 10 15
<210> 4
<211> 16
<212> PRT
<213> Homo sapiens
<400> 4
Lys Val Gly Gly Asn Tyr Asn Tyr Arg Tyr Arg Leu Phe Arg Lys Ser
1 5 10 15
<210> 5
<211> 22
<212> PRT
<213> Homo sapiens
<400> 5
Glu Ile Tyr Gln Ala Gly Ser Lys Pro Cys Asn Gly Val Gln Gly Phe
1 5 10 15
Asn Cys Tyr Phe Pro Leu
20
<210> 6
<211> 10
<212> PRT
<213> Homo sapiens
<400> 6
Tyr Gln Gly Val Asn Cys Thr Glu Val Pro
1 5 10
<210> 7
<211> 16
<212> PRT
<213> Homo sapiens
<400> 7
Ser Tyr Gln Thr Gln Thr Asn Ser Arg Arg Arg Ala Arg Ser Val Ala
1 5 10 15
<210> 8
<211> 15
<212> PRT
<213> Homo sapiens
<400> 8
Ser Ala Leu Gly Lys Leu Gln Asn Val Val Asn Gln Asn Ala Gln
1 5 10 15
<210> 9
<211> 15
<212> PRT
<213> Homo sapiens
<400> 9
His Val Thr Tyr Val Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala
1 5 10 15
<210> 10
<211> 13
<212> PRT
<213> Homo sapiens
<400> 10
Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln
1 5 10
<210> 11
<211> 19
<212> PRT
<213> Homo sapiens
<400> 11
Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro
1 5 10 15
Thr Glu Ser
<210> 12
<211> 13
<212> PRT
<213> Homo sapiens
<400> 12
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly
1 5 10
<210> 13
<211> 19
<212> PRT
<213> Homo sapiens
<400> 13
Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp
1 5 10 15
Asp Phe Thr
<210> 14
<211> 19
<212> PRT
<213> Homo sapiens
<400> 14
Gln Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro
1 5 10 15
Thr Asn Gly
<210> 15
<211> 19
<212> PRT
<213> Homo sapiens
<400> 15
Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val
1 5 10 15
Asn Phe Asn
<210> 16
<211> 19
<212> PRT
<213> Homo sapiens
<400> 16
Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser
1 5 10 15
Ala Ser Phe
<210> 17
<211> 15
<212> PRT
<213> Homo sapiens
<400> 17
Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu
1 5 10 15
<210> 18
<211> 15
<212> PRT
<213> Homo sapiens
<400> 18
Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg
1 5 10 15
<210> 19
<211> 15
<212> PRT
<213> Homo sapiens
<400> 19
Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr
1 5 10 15
<210> 20
<211> 15
<212> PRT
<213> Homo sapiens
<400> 20
Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala
1 5 10 15
Claims (2)
1.一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂,其特征是:所述的多肽制剂包含如SEQ ID NO.1- SEQ ID NO.20所示的多肽。
2.根据权利要求1所述的一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂的应用,其特征是:应用在药学上可接受的盐或酯或前药,所述的盐或酯或前药包含如SEQ IDNO.1- SEQ ID NO.20所示的多肽。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210368066.0A CN114832099B (zh) | 2022-04-08 | 2022-04-08 | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210368066.0A CN114832099B (zh) | 2022-04-08 | 2022-04-08 | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114832099A true CN114832099A (zh) | 2022-08-02 |
CN114832099B CN114832099B (zh) | 2023-11-28 |
Family
ID=82564262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210368066.0A Active CN114832099B (zh) | 2022-04-08 | 2022-04-08 | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114832099B (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112034174A (zh) * | 2020-03-20 | 2020-12-04 | 中国人民解放军军事科学院军事医学研究院 | 一种多肽芯片及其在病毒检测上的应用 |
WO2021035325A1 (pt) * | 2019-08-27 | 2021-03-04 | Fundação Oswaldo Cruz | Receptáculo proteico, polinucleotideo, vetor, cassete de expressão, célula, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, uso do receptáculo, e, kit diagnóstico |
WO2021163371A1 (en) * | 2020-02-12 | 2021-08-19 | La Jolla Institute For Immunology | Coronavirus t cell epitopes and uses thereof |
WO2021194940A1 (en) * | 2020-03-27 | 2021-09-30 | Children's National Medical Center | Sars-cov-2-specific t cells and methods of treatment using them |
WO2021219897A1 (en) * | 2020-05-01 | 2021-11-04 | Vaccibody As | Betacoronavirus prophylaxis and therapy |
WO2021236854A1 (en) * | 2020-05-19 | 2021-11-25 | Gritstone Bio, Inc. | Sars-cov-2 vaccines |
WO2021233913A1 (en) * | 2020-05-19 | 2021-11-25 | R.G.C.C. Holdings AG | Novel cov-2 antibodies |
CN113735947A (zh) * | 2021-09-22 | 2021-12-03 | 四川大学 | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p48及其应用 |
CN113735946A (zh) * | 2021-09-22 | 2021-12-03 | 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p38及其应用 |
WO2021252821A1 (en) * | 2020-06-11 | 2021-12-16 | Mbf Therapeutics Inc. | Enhanced immunogenic dna/rna compositions and methods |
WO2022031790A1 (en) * | 2020-08-05 | 2022-02-10 | The Cleveland Clinic Foundation | Multi-epitope vaccine |
WO2022039126A1 (ja) * | 2020-08-17 | 2022-02-24 | ブライトパス・バイオ株式会社 | SARS-CoV-2予防抗原ペプチドおよびその使用 |
-
2022
- 2022-04-08 CN CN202210368066.0A patent/CN114832099B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021035325A1 (pt) * | 2019-08-27 | 2021-03-04 | Fundação Oswaldo Cruz | Receptáculo proteico, polinucleotideo, vetor, cassete de expressão, célula, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, uso do receptáculo, e, kit diagnóstico |
WO2021163371A1 (en) * | 2020-02-12 | 2021-08-19 | La Jolla Institute For Immunology | Coronavirus t cell epitopes and uses thereof |
CN112034174A (zh) * | 2020-03-20 | 2020-12-04 | 中国人民解放军军事科学院军事医学研究院 | 一种多肽芯片及其在病毒检测上的应用 |
WO2021194940A1 (en) * | 2020-03-27 | 2021-09-30 | Children's National Medical Center | Sars-cov-2-specific t cells and methods of treatment using them |
WO2021219897A1 (en) * | 2020-05-01 | 2021-11-04 | Vaccibody As | Betacoronavirus prophylaxis and therapy |
WO2021236854A1 (en) * | 2020-05-19 | 2021-11-25 | Gritstone Bio, Inc. | Sars-cov-2 vaccines |
WO2021233913A1 (en) * | 2020-05-19 | 2021-11-25 | R.G.C.C. Holdings AG | Novel cov-2 antibodies |
WO2021252821A1 (en) * | 2020-06-11 | 2021-12-16 | Mbf Therapeutics Inc. | Enhanced immunogenic dna/rna compositions and methods |
WO2022031790A1 (en) * | 2020-08-05 | 2022-02-10 | The Cleveland Clinic Foundation | Multi-epitope vaccine |
WO2022039126A1 (ja) * | 2020-08-17 | 2022-02-24 | ブライトパス・バイオ株式会社 | SARS-CoV-2予防抗原ペプチドおよびその使用 |
CN113735947A (zh) * | 2021-09-22 | 2021-12-03 | 四川大学 | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p48及其应用 |
CN113735946A (zh) * | 2021-09-22 | 2021-12-03 | 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p38及其应用 |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
CN114832099B (zh) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111450244B (zh) | 一种防治冠状病毒感染的细胞组合及其应用 | |
CN109942693B (zh) | 一种微小隐孢子虫的ctl表位多肽及其应用和疫苗 | |
CN113528549B (zh) | 编码新型冠状病毒b.1.351突变株抗原的dna分子、dna疫苗及应用 | |
CN113801208B (zh) | 一种新型冠状病毒的t细胞免疫检测方法 | |
CN113528548A (zh) | 新型冠状病毒dna疫苗 | |
CN114832099A (zh) | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 | |
CN114907452B (zh) | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 | |
CN115975924A (zh) | Ctl细胞的制备方法和应用 | |
CN115028737A (zh) | 一种nk细胞培养用滋养细胞 | |
CN113528546B (zh) | 编码新型冠状病毒p.1突变株抗原的dna分子、dna疫苗及应用 | |
CN115976108A (zh) | 一种表达PCV2、PCV3 Cap蛋白的重组伪狂犬病毒载体、构建方法与应用 | |
CN113429481B (zh) | 一种靶向树突状细胞的纳米抗体分子及应用 | |
CN114907453B (zh) | 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽 | |
CN114949194B (zh) | 一种用于治疗SARS-CoV-2病毒感染的多肽制剂 | |
CN112940109B (zh) | 识别ebv抗原的t细胞受体及其应用 | |
CN114907454A (zh) | 一种用于治疗SARS-CoV-2病毒感染的N蛋白多肽 | |
CN105693828A (zh) | 一种新的eb病毒ebna1表位肽及其在ebv相关疾病的诊断、治疗和预防中的用途 | |
CN109535231B (zh) | 人T细胞病毒抗原蛋白Tax的CTL特异性识别表位及其应用 | |
CN113248577A (zh) | 一种以腺病毒为载体的冠状病毒疫苗及其制备方法 | |
CN112209992B (zh) | 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用 | |
CN114657191B (zh) | 一种EBNA3A截短mRNA相关疫苗及其制备方法和应用 | |
CN114573667B (zh) | SARS-CoV-2病毒B.1.1.529突变株DNA疫苗及应用 | |
CN112209996B (zh) | 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用 | |
CN111944022B (zh) | 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用 | |
CN117448362A (zh) | 编码冠状病毒抗原的重组dna分子、dna疫苗及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |